EX-32.1 10 a94549exv32w1.htm EXHIBIT 32.1 exv32w1
 

EXHIBIT 32.1

               The following certifications are being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350 and in accordance with SEC Release No. 33-8238. These certifications shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Certification of Chief Executive Officer

               Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Spectrum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby certifies, to his knowledge, that:

    (i) the accompanying Quarterly Report on Form 10-Q of the Company for the period ended September 30, 2003 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
 
    (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

     
Dated: November 13, 2003                /s/ Rajesh C. Shrotriya
   
    Rajesh C. Shrotriya, M.D.
    Chief Executive Officer

               A signed original of this written statement required by Section 906 has been provided to Spectrum Pharmaceuticals, Inc. and will be retained by Spectrum Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

Certification of Acting Chief Financial officer

               Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Spectrum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby certifies, to his knowledge, that:

    (i) the accompanying Quarterly Report on Form 10-Q of the Company for the period ended September 30, 2003 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
 
    (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

     
Dated: November 13, 2003                /s/ JOHN L. McMANUS
   
    John L. McManus
    Vice President Finance and Strategic Planning

               A signed original of this written statement required by Section 906 has been provided to Spectrum Pharmaceuticals, Inc. and will be retained by Spectrum Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.